

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket No. 00-388-A

Application No. 09/851,743  
 Filing Date: May 9, 2001  
 First Named Inventor Nolan et al.  
 Group Art Unit 1614  
 Examiner Name Unassigned

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
3		5,330,997		Mylari et al.	July 19, 1994	
		6,214,991	B1	Jones et al.	April 10, 2001	
		4,868,301		Mylari et al.	September 19, 1989	
		5,236,945		Mylari et al.	August 17, 1993	
		4,717,725		York, Jr.	January 5, 1988	
		5,700,819		Aotsuka et al.	December 23, 1997	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
3		WO	99/50268	A2	The Institutes for Pharmaceutical Discovery, Inc.	10/07/99		
		WO	00/32180	A2	The Institutes for Pharmaceutical Discovery, Inc.	06/08/00		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).


<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231


# RECEIVED

SEP 04 2002

TECH CENTER 1600/2900

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application No.	09/851,743
				Filing Date:	May 9, 2001
				First Named Inventor	Nolan et al.
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	2	Attorney Docket No.	00-388-A

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
7		AWATA et al. "Effect of an Aldose Reductase Inhibitor, CT-112, on Healing of the Corneal Epithelium in Galatose-Fed Rats", Journal of Ocular Pharmacology Volume 4, Number 3, 1998 pages 195-201.	

Examiner Signature		Date Considered	1/7/03
--------------------	---	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231